Paclitaxel Chemotherapy in Refractory Epithelial Ovarian Cancer : A 32 Cycle Experience

Abstract

Objective To report our experience in using 200 mg/m2 paclitaxel every three weeks in platinum resistant epithelial ovarian cancer patients between September 1994 August 1995.

Subjects Platinum-resistant epithelial ovarian cancer recruited for Taxol Chemotherapy between September 1994-August 1995.

Main outcome measures Response of tumour to chemotherapy according to WHO criteria.

Results The patients tolerated this regimen fairly well, acheiving one complete response, two stable disease and one progressive disease.

Conclusion Paclitaxel may be considered for refractory epithelial ovarian cancer patients with tolerable toxicity.